# Alzheimer's Breakthrough: Targeting Inflammation and Proteins

Newsy: Alzheimer’s News Weekly
Published: 2026-11-16T12:30:05.128Z
Source: https://newsyai.com/edition/50c50e95-0252-4e17-8b4a-40a33aeeabaa
Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md

---

**Alzheimer’s Treatment Briefing: New Inflammation Target, Oral Options, and Protective Protein Boosts**  
**Coverage period: November 9–16, 2026**

Broad searches across news outlets, research databases, regulatory announcements, and trial registries for the past seven days highlight a new clinical trial targeting brain inflammation, fresh lab advances with protective proteins and small molecules, and major data readouts expected at the CTAD conference opening today in Boston. These add practical and forward-looking insights without overlapping prior editions. Here are the key stories, ranked by potential near-term relevance to care and development speed.

**1. Roche launches new Phase II trial of oral drug targeting brain inflammation in early Alzheimer’s**  
**Overview**  
Roche/Genentech is starting TARBELA-AD, a Phase II study of RG6434, an investigational once-daily pill that blocks the NLRP3 protein involved in harmful brain inflammation. The trial focuses on people with early symptomatic Alzheimer’s and complements the company’s ongoing work with trontinemab (an amyloid-clearing antibody delivered via a special “shuttle” for better brain entry). Updated early data on trontinemab’s rapid amyloid removal and the design of its Phase III prevention study (PrevenTRON) will be shared at CTAD this week.[[1]](https://www.gene.com/media/press-releases/15142/2026-11-09/genentech-and-roche-present-new-data-acr)

**Why this matters**  
Alzheimer’s involves more than just amyloid plaques—it’s like a fire where inflammation acts as extra fuel that damages brain cells. This pill aims to douse that fire directly with an easy-to-take oral medicine, potentially working alongside amyloid-clearing therapies. If it succeeds, it could expand options beyond infusions and support a multi-pronged approach for earlier stages of the disease.

**2. AriBio prepares to unveil top-line Phase 3 results for oral Alzheimer’s pill at CTAD**  
**Overview**  
AriBio completed its global Phase 3 POLARIS-AD trial of AR1001, a once-daily oral pill that inhibits PDE5 (an enzyme involved in nerve cell signaling) in 1,535 people with early Alzheimer’s. Top-line efficacy and safety data from the 52-week study will be presented at the CTAD conference opening November 16.[[2]](https://biz.chosun.com/en/en-science/2026/11/11/BZNVB2PD5JHOTDQFQF43F65VII/)

**Why this matters**  
Most current approved treatments require IV infusions. An effective pill could make treatment far more convenient and accessible, like switching from hospital visits to a daily home medication. Positive results would mark a significant step toward simpler, broader use of disease-modifying therapies.

**3. UCLA identifies candidate drug (DDL-357) that boosts protective brain protein and improves memory in Alzheimer’s mice**  
**Overview**  
UCLA researchers found that DDL-357 increases levels of secreted clusterin (sCLU), a natural protective protein. In mouse models, it lowered toxic phospho-tau, improved mitochondrial function, reduced brain inflammation signals, and enhanced performance on memory tests. The work was published in *npj Drug Discovery*.[[3]](https://www.uclahealth.org/news/release/candidate-drug-boosts-protective-brain-protein-mice-has)

**Why this matters**  
Think of clusterin as a built-in cleanup crew that helps prevent toxic protein buildup and supports brain cell energy. Boosting it with a small molecule offers a fresh way to restore balance rather than just clearing damage after it occurs. Early results suggest it could complement existing treatments and potentially help restore some cognitive function—though it remains years from human testing.

**4. Alzheon launches second Phase 3 trial of oral anti-amyloid drug focused on high-risk APOE4 carriers**  
**Overview**  
Alzheon has begun ORION-E4, its second Phase 3 study of oral valiltramiprosate (ALZ-801), targeting people with mild cognitive impairment who carry two copies of the APOE4 gene (a major risk factor). New analyses from the prior APOLLOE4 trial show it reduced certain brain microbleeds and sustained biomarker improvements.[[4]](https://alzheon.com/alzheon-highlights-orion-e4-phase-3-trial-launch-for-oral-valiltramiprosate-alz-801-and-expansion-of-its-oral-anti-amyloid-aggregation-inhibitor-portfolio-at-ctad-2026-conference-in-boston-november-1/)

**Why this matters**  
APOE4 carriers face higher risk and sometimes different responses to treatments. An oral option tailored with data from this group could lead to more personalized strategies, potentially with a better safety profile regarding brain swelling or bleeding compared to some antibody therapies.

**What this means for care right now**  
- Approved anti-amyloid treatments (such as lecanemab and donanemab) remain options for eligible early-stage patients; discuss monitoring, side-effect management, and personalized plans with your doctor.  
- Lifestyle factors (heart health, exercise, sleep, social engagement) continue to support brain health.  
- Clinical trial participation is a key way to access emerging approaches, including oral candidates and prevention studies—tools like trial registries can help match patients.  
- The CTAD conference (November 16–19) is expected to deliver important updates on long-term data and new mechanisms; watch for announcements on inflammation targets, oral pills, and prevention trials.  
- Research is advancing convenient oral options and multi-target strategies that could refine and expand future care.

**Sources**  
- Genentech/Roche press release on TARBELA-AD trial launch and CTAD presentations (November 9–10, 2026).[[1]](https://www.gene.com/media/press-releases/15142/2026-11-09/genentech-and-roche-present-new-data-acr)  
- ChosunBiz and related coverage of AriBio AR1001 Phase 3 data at CTAD (November 11, 2026).[[2]](https://biz.chosun.com/en/en-science/2026/11/11/BZNVB2PD5JHOTDQFQF43F65VII/)  
- UCLA Health release on DDL-357 clusterin-boosting compound (November 13, 2026).[[3]](https://www.uclahealth.org/news/release/candidate-drug-boosts-protective-brain-protein-mice-has)  
- Alzheon announcement on ORION-E4 Phase 3 launch and APOLLOE4 analyses (November 10, 2026).[[4]](https://alzheon.com/alzheon-highlights-orion-e4-phase-3-trial-launch-for-oral-valiltramiprosate-alz-801-and-expansion-of-its-oral-anti-amyloid-aggregation-inhibitor-portfolio-at-ctad-2026-conference-in-boston-november-1/)  
- Comprehensive web searches for Alzheimer’s news, trials, and announcements covering November 9–16, 2026 (conducted November 16, 2026).  

Research continues to layer practical improvements onto existing options while exploring innovative paths forward.
